Are p53 Antibodies a Diagnostic Indicator for Patients with Oral Squamous Cell Carcinoma? Systematic Review and Meta-Analysis

Zhicheng Yang, Ling Li, Zhiwei Xu, Xiao-Dong Sui, Feng Shuang, Jun ZhangAsian 2016 · DOI

Abstract

This meta-analysis suggests that the use of s-p53-antibodies has potential diagnostic value with relatively high sensitivity and specificity for OSCC particularly with serum specimens for discrimination of OSCCs from healthy controls. However, its discrimination power is not perfect because of low sensitivity.

Introduction

Oral Squamous Cell Carcinoma (OSCC) is a highly aggressive malignancy often diagnosed at advanced stages, leading to poor prognosis and high mortality rates. While early detection significantly improves survival, early-stage OSCC is frequently asymptomatic. Current diagnostic gold standards, such as tissue biopsies, are invasive, expensive, and often inconvenient for routine screening. Researchers have long sought non-invasive "liquid biopsy" biomarkers in serum. The p53 protein is a well-known tumor suppressor, and antibodies against its mutated forms (s-p53-Abs) often appear in the blood of cancer patients. However, previous studies on the diagnostic accuracy of these antibodies for OSCC have yielded inconsistent results. This meta-analysis provides a definitive quantitative assessment of their clinical utility.

Methodology

A comprehensive literature search was conducted across PubMed and EMBASE (up to October 2014). From an initial pool of 150 studies, 7 high-quality clinical reports were selected based on their ability to provide sufficient data for $2 \times 2$ diagnostic tables.

Key methodological features included:

  • Quality Assessment: The QUADAS (Quality Assessment of Studies of Diagnostic Accuracy) tool was used to ensure high methodological standards.
  • Statistical Modeling: Fixed and random-effects models were employed to pool the Positive Likelihood Ratio (PLR), Negative Likelihood Ratio (NLR), and Diagnostic Odds Ratio (DOR).
  • Bias Detection: Spearman correlation was used to check for "threshold effects," and funnel plots assessed potential publication bias.

Study Characteristics and Datasets

The meta-analysis synthesized data from 7 eligible studies, encompassing a total sample size of 1,079 serum samples from OSCC patients and 2,260 samples from controls (healthy volunteers or patients with benign diseases). The studies provided geographic diversity, with data originating from Germany, Italy, and India.

Table 1: Characteristics of the studies included in the meta-analysis, showing assay methods and raw diagnostic data (TP, FP, FN, TN).

Results and Analysis

The Specificity-Sensitivity Gap

The most striking finding is the imbalance in diagnostic performance. The s-p53-Ab test is highly specific (89%), meaning a positive result is a very strong indicator of cancer. However, its sensitivity is low (23%), meaning it fails to detect the disease in nearly 77% of affected patients.

Quantitative Diagnostic Estimates

The pooled quantitative estimates for s-p53-Abs in diagnosing OSCC were:

  • Sensitivity: 0.23 (95% CI: 0.19–0.27)
  • Specificity: 0.89 (95% CI: 0.86–0.92)
  • Positive Likelihood Ratio (PLR): 2.06 (95% CI: 1.35–3.15)
  • Negative Likelihood Ratio (NLR): 0.85 (95% CI: 0.80–0.90)
  • Diagnostic Odds Ratio (DOR): 2.47 (95% CI: 1.49–4.12)
  • Area Under the Curve (AUC): 0.74
Figure 1: Forest plot of the Diagnostic Odds Ratio (DOR) for s-p53-Abs, showing a pooled DOR of 2.47.

With an AUC of 0.74, the test has reasonable accuracy. The pooled DOR of 2.47 indicates that the odds of a positive test result are significantly higher in OSCC patients than in controls, though the wide confidence intervals in some individual studies suggest variability in performance across different clinical settings.

Discussion and Conclusion

While s-p53-Abs demonstrate potential as a diagnostic indicator, their extremely low sensitivity suggests they are currently insufficient as a standalone screening tool. The researchers found significant heterogeneity in the Negative Likelihood Ratio (NLR), likely due to variations in assay methods (ELISA vs. immunoblotting) and control group compositions.

Future research should focus on combining s-p53-Abs with other biomarkers to create a multi-marker panel that maintains high specificity while boosting sensitivity. Additionally, more prospective studies are needed to evaluate diagnostic accuracy in Stage I and II OSCC, which is the most critical window for clinical intervention.

Summary updated

Abstract

This meta-analysis suggests that the use of s-p53-antibodies has potential diagnostic value with relatively high sensitivity and specificity for OSCC particularly with serum specimens for discrimination of OSCCs from healthy controls. However, its discrimination power is not perfect because of low sensitivity.
BibTeX
@inproceedings{yang2016are,
  author = {Zhicheng Yang and Ling Li and Zhiwei Xu and Xiao-Dong Sui and Feng Shuang and Jun Zhang},
  title = {{Are p53 Antibodies a Diagnostic Indicator for Patients with Oral Squamous Cell Carcinoma? Systematic Review and Meta-Analysis}},
  booktitle = {Asian},
  year = {2016},
  doi = {10.7314/apjcp.2016.17.1.109},
}
Figure